Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
3.260
+0.220 (7.24%)
At close: May 28, 2025, 4:00 PM
3.250
-0.010 (-0.31%)
After-hours: May 28, 2025, 5:39 PM EDT
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
252.70M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SLDB News
- 10 hours ago - Solid Biosciences to Participate at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 13 days ago - Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 27 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Solid Biosciences to Participate at The Citizens Life Sciences Conference - GlobeNewsWire
- 4 weeks ago - Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting - GlobeNewsWire
- 7 weeks ago - Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha
- 2 months ago - Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul - New York Post
- 2 months ago - Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewsWire